AI-Driven Drug Discovery (BioAI Pharma) and Its Impact on Healthcare Equity (2025 Assessment) AI-driven drug discovery is reshaping pharmaceutical development, offering dual implications for healthcare equity: it can accelerate equitable global health resource allocation but may also exacerbate disp…
AI-Driven Drug Discovery (BioAI Pharma): Development of Life Science Large Models (Comprehensive Analysis Based on 2025 Technological Advances and Industry Practices) 1. Core Architecture and Data Integration in Life Science Models BioAI Pharma relies on multimodal life science models that integrate…
Contraindications of COVID-19 Antiviral Therapies: A Comprehensive Analysis (As of May 2025) I. Key Contraindications of Major Antivirals 1. Paxlovid (Nirmatrelvir/Ritonavir) Absolute Contraindications: Hypersensitivity to nirmatrelvir or ritonavir (e.g., Stevens-Johnson syndrome, toxic epidermal ne…
BioAI Cell: AI-Driven Simulation of Cellular Behavior and Drug Discovery Revolution (As of May 2025) I. Virtual Cells: Digital Twins in Life Sciences 1. Definition and Core Framework BioAI Cell is an interdisciplinary field that uses AI to simulate, analyze, and manipulate cellular behavior. Key obj…
BioAI Pharma: Convergence of Biotechnology, AI, and Drug Development (As of May 2025) I. Definition and Technical Framework BioAI Pharma integrates biotechnology, artificial intelligence, and pharmaceutical R&D to transform drug discovery and development. Its core framework spans: Data Layer: Ag…